Literature DB >> 26603549

PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?

Steven P Rowe1, Margarita Mana-Ay2, Mehrbod S Javadi1, Zsolt Szabo1, Jeffrey P Leal3, Martin G Pomper1, Kenneth J Pienta4, Ashley E Ross2, Michael A Gorin5.   

Abstract

Entities:  

Keywords:  Bone metastases; DCFPyL; PET/CT; PSMA; Prostate cancer

Mesh：

Substances：

Year:  2015        PMID： 26603549      PMCID： PMC4698229          DOI： 10.1016/j.clgc.2015.09.011

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  13 in total

1.  The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate.

Authors:  Vincent Helyar; Hosahalli K Mohan; Tara Barwick; Lefteris Livieratos; Gopinath Gnanasegaran; Susan E M Clarke; Ignac Fogelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-17       Impact factor: 9.236

2.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

3.  Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.

Authors:  Mads H Poulsen; Henrik Petersen; Poul F Høilund-Carlsen; Jørn S Jakobsen; Oke Gerke; Jens Karstoft; Signe I Steffansen; Steen Walter
Journal:  BJU Int       Date:  2014-05-22       Impact factor: 5.588

4.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

5.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

Authors:  Piet Ost; Barbara Alicja Jereczek-Fossa; Nicholas Van As; Thomas Zilli; Alexander Muacevic; Kenneth Olivier; Daniel Henderson; Franco Casamassima; Roberto Orecchia; Alessia Surgo; Lindsay Brown; Alison Tree; Raymond Miralbell; Gert De Meerleer
Journal:  Eur Urol       Date:  2015-07-16       Impact factor: 20.096

6.  Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.

Authors:  H Schirrmeister; A Guhlmann; K Elsner; J Kotzerke; G Glatting; M Rentschler; B Neumaier; H Träger; K Nüssle; S N Reske
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

7.  Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Authors:  Steven P Rowe; Michael A Gorin; Hans J Hammers; M Som Javadi; Hazem Hawasli; Zsolt Szabo; Steve Y Cho; Martin G Pomper; Mohamad E Allaf
Journal:  Ann Nucl Med       Date:  2015-08-19       Impact factor: 2.668

8.  Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.

Authors:  Bruce E Hillner; Barry A Siegel; Lucy Hanna; Fenghai Duan; Anthony F Shields; R Edward Coleman
Journal:  J Nucl Med       Date:  2014-02-27       Impact factor: 10.057

9.  Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients.

Authors:  H Palmedo; C Marx; A Ebert; B Kreft; Y Ko; A Türler; R Vorreuther; U Göhring; H H Schild; T Gerhardt; U Pöge; S Ezziddin; H-J Biersack; H Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-24       Impact factor: 9.236

10.  Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer.

Authors:  Luca Giovanella; Massimo Castellani; Sergio Suriano; Teresa Ruberto; Luca Ceriani; Luca Tagliabue; Giovanni Lucignani
Journal:  Tumori       Date:  2011 Sep-Oct
View more
  20 in total

1.  Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake.

Authors:  Xin Li; Steven P Rowe; Jeffrey P Leal; Michael A Gorin; Mohamad E Allaf; Ashley E Ross; Kenneth J Pienta; Martin A Lodge; Martin G Pomper
Journal:  J Nucl Med       Date:  2016-12-08       Impact factor: 10.057

2.  Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Authors:  Yafu Yin; Rudolf A Werner; Takahiro Higuchi; Constantin Lapa; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

Review 3.  18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

Review 4.  Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

5.  Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.

Authors:  Jeffrey J Tosoian; Michael A Gorin; Steven P Rowe; Darian Andreas; Zsolt Szabo; Kenneth J Pienta; Martin G Pomper; Tamara L Lotan; Ashley E Ross
Journal:  Clin Genitourin Cancer       Date:  2016-09-19       Impact factor: 2.872

6.  Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.

Authors:  Stephanie A Harmon; Michael J Tuite; Robert Jeraj
Journal:  Phys Med Biol       Date:  2016-10-03       Impact factor: 3.609

Review 7.  PSMA PET and Radionuclide Therapy in Prostate Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

Review 8.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Authors:  S P Rowe; M A Gorin; M E Allaf; K J Pienta; P T Tran; M G Pomper; A E Ross; S Y Cho
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

9.  A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Authors:  Stephanie A Harmon; Ethan Bergvall; Esther Mena; Joanna H Shih; Stephen Adler; Yolanda McKinney; Sherif Mehralivand; Deborah E Citrin; Anna Couvillon; Ravi A Madan; James L Gulley; Ronnie C Mease; Paula M Jacobs; Martin G Pomper; Baris Turkbey; Peter L Choyke; M Liza Lindenberg
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057

Review 10.  Recent updates and developments in PET imaging of prostate cancer.

Authors:  Steven P Rowe; Geoffrey B Johnson; Martin G Pomper; Michael A Gorin; Spencer C Behr
Journal:  Abdom Radiol (NY)       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.